The complaint for thrombus formation was unable to be confirmed based on the available information.However, this is insufficient information to determine the cause of this event.The complaint review and analysis of all available information fails to indicate a root cause or probable root cause.Unable to determine the cause of the event.Various factors that may contribute to an indeterminable root cause include, but are not limited to, no adequate imaging available, no product return, and no additional information from the site.Based on extensive complaint investigations and reviews, it has been identified that events are not associated with device malfunctions or manufacturing nonconformances.Per the instructions for use (ifu), intracardiac thrombus formation and device thrombosis are known potential adverse events which have been identified as possible complications associated with standard cardiac catheterization procedures.Potential patient risk factors such as atrial fibrillation, systemic disease (e.G., systemic lupus erythematosus, inflammation, and damage to various body tissues, including joints, skin, kidneys, heart, lungs, blood vessels, and brain), valvular disease itself and reduced cardiac ejection fraction can contribute to increased risk of thrombus/thrombosis.These events will continue to be monitored and complaints trending, and control limits are managed and assessed.
|
Upon further review, the event date was updated to reflect the literature article submission date as the true event date is unknown and date of death is also unknown.Article citation: doshi sn, savvoulidis p, mechery a, lawton e, nadir ma.Versacross transseptal system for mitral transcatheter edge-to-edge repair with the pascal repair platform.Struct heart.2023 jun 22;7(6):100203.Doi: 10.1016/j.Shj.2023.100203.Pmid: 38046864; pmcid: pmc10692349.
|